AGEN
Price
$4.50
Change
-$0.02 (-0.44%)
Updated
Aug 25, 11:29 AM (EDT)
Capitalization
144.03M
DMAC
Price
$6.01
Change
-$0.10 (-1.64%)
Updated
Aug 25, 11:19 AM (EDT)
Capitalization
315.82M
72 days until earnings call
TLRY
Price
$1.34
Change
+$0.19 (+16.52%)
Updated
Aug 25, 11:45 AM (EDT)
Capitalization
1.26B
38 days until earnings call
Interact to see
Advertisement

AGEN or DMAC or TLRY

Header iconAGEN vs DMAC vs TLRY Comparison
Open Charts AGEN vs DMAC vs TLRYBanner chart's image
Agenus
Price$4.50
Change-$0.02 (-0.44%)
Volume$200
Capitalization144.03M
DiaMedica Therapeutics
Price$6.01
Change-$0.10 (-1.64%)
Volume$100
Capitalization315.82M
Tilray Brands
Price$1.34
Change+$0.19 (+16.52%)
Volume$200.62K
Capitalization1.26B
AGEN vs DMAC vs TLRY Comparison Chart in %
Loading...
AGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DMAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TLRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
Interact to see
Advertisement
COMPARISON
Comparison
Aug 25, 2025
Stock price -- (AGEN: $4.52DMAC: $6.11TLRY: $1.15)
Brand notoriety: AGEN and DMAC are not notable and TLRY is notable
AGEN and DMAC are part of the Biotechnology industry, and TLRY is in the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: AGEN: 38%, DMAC: 65%, TLRY: 93%
Market capitalization -- AGEN: $144.03M, DMAC: $315.82M, TLRY: $1.26B
$AGEN [@Biotechnology] is valued at $144.03M. $DMAC’s [@Biotechnology] market capitalization is $ $315.82M. $TLRY [@Pharmaceuticals: Generic] has a market capitalization of $ $1.26B. The market cap for tickers in the [@Biotechnology] industry ranges from $ $101.31B to $ $0. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $ $69.41B to $ $0. The average market capitalization across the [@Biotechnology] industry is $ $1.86B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $ $3.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AGEN’s FA Score shows that 0 FA rating(s) are green whileDMAC’s FA Score has 0 green FA rating(s), and TLRY’s FA Score reflects 0 green FA rating(s).

  • AGEN’s FA Score: 0 green, 5 red.
  • DMAC’s FA Score: 0 green, 5 red.
  • TLRY’s FA Score: 0 green, 5 red.
According to our system of comparison, TLRY is a better buy in the long-term than DMAC, which in turn is a better option than AGEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AGEN’s TA Score shows that 4 TA indicator(s) are bullish while DMAC’s TA Score has 5 bullish TA indicator(s), and TLRY’s TA Score reflects 4 bullish TA indicator(s).

  • AGEN’s TA Score: 4 bullish, 6 bearish.
  • DMAC’s TA Score: 5 bullish, 4 bearish.
  • TLRY’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, DMAC is a better buy in the short-term than TLRY, which in turn is a better option than AGEN.

Price Growth

AGEN (@Biotechnology) experienced а -2.38% price change this week, while DMAC (@Biotechnology) price change was +1.33% , and TLRY (@Pharmaceuticals: Generic) price fluctuated +11.65% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.14%. For the same industry, the average monthly price growth was +18.77%, and the average quarterly price growth was +29.32%.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +2.58%. For the same industry, the average monthly price growth was +9.38%, and the average quarterly price growth was +69.46%.

Reported Earning Dates

DMAC is expected to report earnings on Nov 05, 2025.

TLRY is expected to report earnings on Oct 02, 2025.

Industries' Descriptions

@Biotechnology (+2.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

@Pharmaceuticals: Generic (+2.58% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TLRY($1.26B) has a higher market cap than DMAC($316M) and AGEN($144M). AGEN YTD gains are higher at: 64.963 vs. DMAC (12.523) and TLRY (-13.534). DMAC has higher annual earnings (EBITDA): -31.42M vs. AGEN (-74.93M) and TLRY (-2.13B). TLRY has more cash in the bank: 256M vs. DMAC (30M) and AGEN (9.53M). DMAC has less debt than AGEN and TLRY: DMAC (292K) vs AGEN (90.5M) and TLRY (329M). TLRY has higher revenues than AGEN and DMAC: TLRY (821M) vs AGEN (102M) and DMAC (0).
AGENDMACTLRY
Capitalization144M316M1.26B
EBITDA-74.93M-31.42M-2.13B
Gain YTD64.96312.523-13.534
P/E Ratio0.16N/AN/A
Revenue102M0821M
Total Cash9.53M30M256M
Total Debt90.5M292K329M
FUNDAMENTALS RATINGS
AGEN vs DMAC vs TLRY: Fundamental Ratings
AGEN
DMAC
TLRY
OUTLOOK RATING
1..100
124339
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
70
Overvalued
53
Fair valued
PROFIT vs RISK RATING
1..100
10097100
SMR RATING
1..100
1009899
PRICE GROWTH RATING
1..100
604036
P/E GROWTH RATING
1..100
9810094
SEASONALITY SCORE
1..100
505050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TLRY's Valuation (53) in the Biotechnology industry is in the same range as DMAC (70) and is somewhat better than the same rating for AGEN (97). This means that TLRY's stock grew similarly to DMAC’s and somewhat faster than AGEN’s over the last 12 months.

DMAC's Profit vs Risk Rating (97) in the Biotechnology industry is in the same range as TLRY (100) and is in the same range as AGEN (100). This means that DMAC's stock grew similarly to TLRY’s and similarly to AGEN’s over the last 12 months.

DMAC's SMR Rating (98) in the Biotechnology industry is in the same range as TLRY (99) and is in the same range as AGEN (100). This means that DMAC's stock grew similarly to TLRY’s and similarly to AGEN’s over the last 12 months.

TLRY's Price Growth Rating (36) in the Biotechnology industry is in the same range as DMAC (40) and is in the same range as AGEN (60). This means that TLRY's stock grew similarly to DMAC’s and similarly to AGEN’s over the last 12 months.

TLRY's P/E Growth Rating (94) in the Biotechnology industry is in the same range as AGEN (98) and is in the same range as DMAC (100). This means that TLRY's stock grew similarly to AGEN’s and similarly to DMAC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AGENDMACTLRY
RSI
ODDS (%)
Bullish Trend 4 days ago
85%
Bearish Trend 4 days ago
86%
Bearish Trend 4 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
85%
Bearish Trend 4 days ago
85%
Bearish Trend 4 days ago
90%
Momentum
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
83%
Bullish Trend 4 days ago
78%
MACD
ODDS (%)
Bearish Trend 5 days ago
90%
Bullish Trend 4 days ago
80%
Bullish Trend 4 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
83%
Bullish Trend 4 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
89%
Bullish Trend 4 days ago
82%
Bullish Trend 4 days ago
81%
Advances
ODDS (%)
Bullish Trend 11 days ago
84%
Bullish Trend 6 days ago
84%
Bullish Trend 4 days ago
83%
Declines
ODDS (%)
Bearish Trend 20 days ago
89%
Bearish Trend 15 days ago
81%
Bearish Trend 11 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
82%
Bearish Trend 4 days ago
85%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bearish Trend 4 days ago
89%
Bullish Trend 4 days ago
81%
Bullish Trend 4 days ago
71%
View a ticker or compare two or three
Interact to see
Advertisement
AGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DMAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TLRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
UMBHX29.980.80
+2.74%
Carillon Chartwell Small Cap I
DIEFX15.520.27
+1.77%
Destinations International Equity I
MLVKX31.460.44
+1.42%
BlackRock Advantage Large Cap Val K
PSECX19.140.18
+0.95%
1789 Growth and Income C
JNBZX10.360.09
+0.88%
JPMorgan Income Builder R6

DMAC and

Correlation & Price change

A.I.dvisor indicates that over the last year, DMAC has been loosely correlated with WHWK. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if DMAC jumps, then WHWK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DMAC
1D Price
Change %
DMAC100%
+3.04%
WHWK - DMAC
47%
Loosely correlated
+5.45%
ARCT - DMAC
37%
Loosely correlated
+5.89%
HUMA - DMAC
35%
Loosely correlated
+2.60%
XOMA - DMAC
30%
Poorly correlated
+4.43%
ELDN - DMAC
30%
Poorly correlated
+1.56%
More

TLRY and

Correlation & Price change

A.I.dvisor indicates that over the last year, TLRY has been closely correlated with SNDL. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if TLRY jumps, then SNDL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TLRY
1D Price
Change %
TLRY100%
+3.60%
SNDL - TLRY
76%
Closely correlated
+0.45%
CRON - TLRY
62%
Loosely correlated
+1.56%
CGC - TLRY
62%
Loosely correlated
+2.42%
OGI - TLRY
61%
Loosely correlated
+1.91%
ACB - TLRY
55%
Loosely correlated
+4.39%
More